Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
21 March 2025
| N 00:47 | Zanubrutinib diffhist +6,355 Omid Afkhami-Ardakani talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Zanubrutinib |aOrAn=a |drugClass=Bruton's Tyrosine Kinase (BTK) Inhibitor |indicationType=treatment |indication=Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Waldenström's Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), and Follicular Lymphoma (FL) in adults. |adverseReactions=Decreased neutrophil count, Upper respiratory tract infection,...") | ||||
20 March 2025
| N 10:56 | Reblozyl diffhist +5,813 Omid Afkhami-Ardakani talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Luspatercept-aamt |aOrAn=an |drugClass=Erythroid Maturation Agent |indicationType=treatment |indication=anemia in adult patients. More specifically anemia due to Beta Thalassemia, Myelodysplastic Syndromes (MDS), MDS with Ring Sideroblasts (MDS-RS) or Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). |adverseReactions=Fatigue, Headache, Musc...") | ||||
| N 10:20 | Vadadustat diffhist +19,544 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=vadadustat |indicationType=treatment |indication=VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. |hasBlackBoxWarning=Yes |adverseReactions=*VAFSEO increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE) *Targeting a hemoglobin lev...") | ||||
|
|
09:45 | Meningitis 3 changes history +943 [Alara E. Dagsali (3×)] | |||
|
|
09:45 (cur | prev) +2 Alara E. Dagsali talk contribs | ||||
|
|
09:44 (cur | prev) +39 Alara E. Dagsali talk contribs | ||||
|
|
08:54 (cur | prev) +902 Alara E. Dagsali talk contribs | ||||
19 March 2025
| 15:42 | Burnout (psychology) diffhist +1,343 Badgettrg talk contribs (→Leadership quality: Added Spilg) | ||||
18 March 2025
| N 20:58 | Danicopan diffhist +29,524 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=Danicopan |aOrAn=a |drugClass=medication |indicationType=treatment |indication=VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). |hasBlackBoxWarning=Yes |adverseReactions=*Serious Infections Caused by Encapsulated Bacteria *Hepatic Enzyme Increase *Hyperl...") | ||||
| 20:39 | Alara E. Dagsali diffhist +69 Alara E. Dagsali talk contribs | ||||
| N 20:36 | Ceftobiprole medocaril sodium diffhist +36,115 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=ceftobiprole medocaril sodium |aOrAn=a |drugClass=beta-lactam class of antibiotics |indicationType=treatment |indication='''1.1 Staphylococcus aureus Bloodstream Infection (Bacteremia)''' ZEVTERA is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infection (bacteremia) (SAB), including those with right-sided infective endocarditis, caused by me...") | ||||
|
|
N 19:50 | Pegulicianine 2 changes history +17,295 [Alara E. Dagsali (2×)] | |||
|
|
19:50 (cur | prev) +96 Alara E. Dagsali talk contribs | ||||
| N |
|
19:48 (cur | prev) +17,199 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=User:AED |genericName=pegulicianine |aOrAn=a |drugClass=diagnostic imaging agent |indicationType=diagnosis |indication=LUMISIGHT is indicated for fluorescence imaging in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery. |hasBlackBoxWarning=Yes |adverseReactions=*Anaphylaxis and Other Serious Hyp...") | |||
17 March 2025
| N 18:31 | Air polymer-type A diffhist +5,259 Omid Afkhami-Ardakani talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Air polymer-type A intrauterine foam |aOrAn=an |drugClass=Ultrasound Contrast Agent |indication=sonohysterosalpingography to assess fallopian tube patency in women with known or suspected infertility. |adverseReactions=Pelvic and abdominal pain, Nausea and faintness, Post-procedure spotting |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="col...") | ||||
|
|
m 18:06 | Whipple's disease differential diagnosis 7 changes history +511 [Gerald Chi (7×)] | |||
| m |
|
18:06 (cur | prev) −4 Gerald Chi talk contribs | |||
| m |
|
18:05 (cur | prev) 0 Gerald Chi talk contribs | |||
| m |
|
18:05 (cur | prev) +345 Gerald Chi talk contribs | |||
| m |
|
18:02 (cur | prev) +67 Gerald Chi talk contribs (→Differentiating Whipple's disease from other Diseases) | |||
| m |
|
17:59 (cur | prev) +6 Gerald Chi talk contribs | |||
| m |
|
17:56 (cur | prev) −1 Gerald Chi talk contribs | |||
| m |
|
17:56 (cur | prev) +98 Gerald Chi talk contribs Tag: Visual edit: Switched | |||
| N 15:30 | Trikafta diffhist +7,857 Omid Afkhami-Ardakani talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Elexacaftor, Tezacaftor, and Ivacaftor |aOrAn=a |drugClass=Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator |indicationType=treatment |indication=cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive based on clinical and/or in vitro data. If the patient's genotype is unkn...") | ||||
| N 14:58 | Fluorodopa F 18 diffhist +4,778 Omid Afkhami-Ardakani talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=fluorodopa F 18 |aOrAn=a |drugClass=Radiopharmaceutical Diagnostic Agent |indication=indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). |adverseReactions=Injection site pain |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarn...") | ||||
14 March 2025
| N 10:35 | Brolucizumab–dbll diffhist +6,665 Omid Afkhami-Ardakani talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Brolucizumab-dbll |aOrAn=a |drugClass=Vascular Endothelial Growth Factor (VEGF) Inhibitor |indicationType=treatment |indication=Neovascular (Wet) Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) |adverseReactions=Vision blurred, Cataract, Conjunctival hemorrhage, Eye pain, and Vitreous floaters. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWa...") | ||||